Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial (Q29307563)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: August 2015)

Language	Label	Description	Also known as
English	Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial	scientific article (publication date: August 2015)

Statements

scholarly article

0 references

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial (English)

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2815%2960158-1

9 April 2017

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

Danish Saleheen

6

0 references

John J. P. Kastelein

2

object named as

John J P Kastelein

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2815%2960158-1

9 April 2017

1

object named as

G Kees Hovingh

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2815%2960158-1

9 April 2017

author name string

Sander J H van Deventer

3

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2815%2960158-1

9 April 2017

Patrick Round

4

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2815%2960158-1

9 April 2017

John Ford

5

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2815%2960158-1

9 April 2017

Daniel J Rader

7

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2815%2960158-1

9 April 2017

H Bryan Brewer

8

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2815%2960158-1

9 April 2017

Philip J Barter

9

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2815%2960158-1

9 April 2017

language of work or name

0 references

publication date

August 2015

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2815%2960158-1

9 April 2017

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2815%2960158-1

9 April 2017

386

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2815%2960158-1

9 April 2017

452-460

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2815%2960158-1

9 April 2017

9992

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2815%2960158-1

9 April 2017

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of torcetrapib in patients at high risk for coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of dalcetrapib in patients with a recent acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Torcetrapib impairs endothelial function in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipoprotein(a) as a cardiovascular risk factor: current status

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

HDL and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

HDL cholesterol efflux capacity and incident cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960158-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q29307563&oldid=2065793820"